Fed. Circ. Wipes Out Medicines Co.'s Angiomax Patents

By Ryan Davis (July 2, 2015, 3:46 PM EDT) -- The Federal Circuit on Thursday invalidated two of The Medicines Co.'s patents for the blood thinning drug Angiomax, finding that the claimed process was offered for sale before the patent applications were filed, in a victory for Hospira Inc., which is planning a generic version of the drug.

The decision reversed a lower court ruling that found that the patents are valid, but that Hospira didn't infringe them. The Medicines Co. appealed the noninfringement finding, while Hospira appealed the finding that the patents are valid.

The Federal Circuit sided with Hospira and found that the patents are invalid under the on-sale...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!